Pharmaceutical distributor Oriola issues a profit warning and now expects adjusted EBITDA for 2026 to be in line with or higher than last year’s EUR 35.1 million.
An increase was previously expected.
The forecast cut is due to higher-than-expected operating costs in October, mainly as a result of disruptions in the Swedish supply chain.
